Panax ginseng has long been used as natural medicine and health food all over the world.
Cancer is a major cause of death worldwide and its prognosis likely depends on the immune system during
tumor treatment. In this study, ginseng berry
polysaccharides were evaluated for their
immunostimulant and anti-
cancer effects. Ginseng berry
polysaccharide portion (GBPP) was used to investigate its effects on anti-complementary activity, peritoneal macrophage activation, and natural killer (NK) cell cytotoxicity. Moreover, both intravenous (i.v.) and
oral administration of GBPP prior to B16-BL6
melanoma implantation in mice was evaluated. GBPP significantly increased the anti-complementary activity and
cytokine production including
interleukin (IL)-6,
IL-12, and
tumor necrosis factor (TNF)-α, dose-dependently. Splenocytes obtained after i.v. administration of GBPP showed cytolytic activity in Yac-1 cells in proportion to the E/T ratio. In addition, GBPP enhanced the production of
interferon (IFN)-γ and
granzyme B of NK cells. For the experimental
lung cancer, compared with control mice, GBPP delivered by i.v. suppressed
cancer by 48% at 100 μg/mouse, while a 37% reduction was achieved by
oral administration. Deficient of NK cells in animal model demonstrated that the anti-
cancer effect of GBPP was through NK cell activation. Results of this study suggest that ginseng berry
polysaccharides, owing to their modulation of the immune response, can be a potential curative applicant for the prevention and treatment of
tumors.